Moreover, we have shown that high SK1 expression in the ER+/HER2+ breast cancer tumours is correlated with increased patient survival and reduced disease recurrence on Tamoxifen (Long et al, 2010a), thereby demonstrating a protective role for SK1 in this tumour phenotype (Long et al, 2010a). Here, SPHK1 is linked to breast carcinoma.